Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma

Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Alessandro D. Santin


Ovarian cancer is the most common cause of gynecologic cancer death in the United States with 22,530 newly diagnosed cases and 13,980 deaths annually. There has been a miniscule, approximately 2.3% decrease, each year in the death rates from ovarian cancer over the past few decades (1). Although most patients with advanced ovarian cancer respond to initial platinum-based chemotherapy, 70% will relapse and ultimately become resistant, refractory, or unable to receive platinum-based chemotherapy owing to cumulative toxic effects (2,3). This has led to a paradigm shift in the approach to the treatment of ovarian cancer with precision medicine and additional targeted therapies becoming part of the standard treatment regimen.